Why This Study Matters

Acupuncture is one of the most common non-drug options people try for migraine. It shows up in treatment guidelines, headache clinics offer it, and many patients ask about it. Yet the evidence has always been hard to read, because a lot of acupuncture research compares needling against usual care or a waiting list. When people know they are getting an active, hands-on treatment, expectation alone can lower reported pain. That makes it difficult to tell how much benefit comes from the needles themselves.

A systematic review and meta-analysis published in the Journal of Pain Research in July 2026 tried to isolate that question. The authors pooled only randomized trials that compared real acupuncture against sham acupuncture, and only in adults with migraine without aura. This is a narrower and more demanding bar than most prior reviews, and it gives a cleaner look at whether acupuncture does more than placebo.

What "Sham-Controlled" Means

To understand why this analysis is stricter than most, it helps to know what the comparison group looked like.

This design is not perfect. Sham needling is not completely inert, and some placebo methods may still trigger mild physiological effects. The review authors flagged this directly, noting that trials using penetrating or more intense sham procedures tended to show smaller gaps between the real and sham groups. That is an important caveat, because it means the "true" placebo bar may be even higher than these numbers suggest.

How the Study Was Done

The researchers searched six databases through February 2026 and followed standard systematic review methods, with a protocol registered in advance. They included only randomized controlled trials in adults diagnosed with migraine without aura, and only trials that used a sham comparator. Trials that combined acupuncture with other active treatments were excluded unless the effect of acupuncture alone could be separated out.

Most trials used manual acupuncture at standardized migraine-related points, while one used electroacupuncture and another used more intensified manual stimulation. Outcomes were measured anywhere from four to twenty weeks after treatment. The primary outcome was monthly migraine days. Secondary outcomes were migraine-specific quality of life, pain intensity, and headache impact measured with the HIT-6 questionnaire.

What They Found

Results were pooled as standardized effect sizes rather than raw numbers, because the trials used different scales. A positive value here favors acupuncture over sham. The next section explains how to interpret the size of these numbers.

For migraine frequency and pain intensity, acupuncture separated from sham by a small to moderate amount, and these estimates were statistically significant. Importantly, the migraine-days result had zero measured heterogeneity, meaning the trials agreed closely with each other, and leaving out any single trial did not change the picture.

Headache impact also favored acupuncture, but the trials disagreed a lot on the size of that effect. Quality of life leaned toward acupuncture without reaching statistical significance. In both cases, the authors traced the disagreement to a small number of specific trials, and removing those trials shrank the inconsistency without flipping the direction of the result.

Reading the Effect Sizes

The numbers above are standardized mean differences, reported as Hedges' g. This is a common way to combine trials that measured the same idea on different scales. It is not a count of migraine days.

Whether a moderate effect is meaningful depends on the person. For someone with frequent, disabling attacks, even a modest reduction in frequency or intensity can matter for daily function and for how much acute medication they need. For someone with milder or infrequent attacks, the same effect may feel less noticeable.

Why the Certainty Is Still Low

This is the part that keeps the study honest. The authors graded the strength of the evidence using GRADE, a standard framework, and the ratings were not reassuring.

Low or very low certainty means future, better-designed trials could plausibly change these conclusions. The downgrades came from a few recurring problems: the small number of trials per outcome, small sample sizes, and inconsistent reporting of how patients were randomized and how allocation was concealed. Using a formal risk-of-bias tool, most trials landed in the "some concerns" category, a minority were judged high risk, and only a few met the bar for low risk across every domain.

None of this means acupuncture does not work. It means the current evidence base is thin and uneven, and the results should be read as suggestive rather than definitive.

Limitations to Keep in Mind

• All trials were from one country. Every included study came from China, which limits how far the results generalize to other settings and practice styles.
• Few trials, small samples. Only eight trials and 659 people total, with several outcomes resting on just five or six studies. That makes the estimates less precise and more sensitive to any single study.
• Sham is not uniform. Different placebo methods may deliver different amounts of real stimulation, which complicates the comparison and may understate or overstate the true gap.
• Migraine without aura only. The review deliberately focused on this subtype to reduce noise. The findings do not directly speak to migraine with aura, which involves different underlying mechanisms.
• Reporting gaps. Inconsistent description of randomization and analysis methods lowered confidence across the board.